HCM
HUTCHMED
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · HK
$13.67
−1.09%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$13.68
From 52W high−21.66%
Volume15795.00
Market cap$2.38B
P/E (TTM)139.5x
P/S (TTM)4.3x
Div yield—
Key dataSep 18, 2026
Open
$13.68
From 52W high
−21.66%
Volume
15795.00
Market cap
$2.38B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−54.5x
P/E (TTM)
139.5x
RSI (14)
59.3
MomentumView details →
1D Return
−1.09%
YTD Return
+2.55%
SummaryUpdated Jun 1, 2026
HUTCHMED (China) Limited (NASDAQ:HCM) is a Hong Kong-based biopharmaceutical company that was founded in 2000 and went public in 2016. Originally known as Hutchison China MediTech Limited, the company rebranded to HUTCHMED in May 2021. The company specializes in discovering, developing, and commercializing targeted cancer therapies and immunological treatments, with operations spanning Hong Kong and international markets. HUTCHMED has evolved from a research-focused organization into a commercial-stage company with multiple approved drugs and a robust pipeline of investigational treatments.
Similar companies
Latest newsMore news →
AstraZeneca reported positive late-stage trial results for a combination of its lung cancer drugs Tagrisso and Orpathys, potentially paving the way for global approval.34d agoHUTCHMED received NMPA approval for ORPATHYS® for the treatment of gastric cancer patients with MET amplification in China.80d ago